Clinical Trials | December 17, 2024
Merck to discontinue KeyVibe and Keyform clinical trials
Merck has also decided to end the favezelimab clinical development program
Merck has also decided to end the favezelimab clinical development program
SPARC to receive 55% equity in Tiller Therapeutics
First and only PARP inhibitor to improve overall survival in early breast cancer
Showing High Overall Response Rate (ORR) with durable responses and favorable safety profile in patients with heavily pretreated multiple myeloma
Performed within GENEWIZ from Azenta Life Sciences' CLIA-certified and CAP-accredited state-of-the-art clinical genomics laboratory
The company uses iPS cells to develop treatments for diseases relating to the kidney
CSPC will receive an upfront payment of $100 million from AstraZeneca
The company will also share results in two additional posters for deuruxolitinib
ALS patients experience neuroinflammation and rapid neurodegeneration
H.coagulans is, unlike other general lactobacillus, characterized by spore formation, giving it resistance to acid and heat
Subscribe To Our Newsletter & Stay Updated
